N-[(1S)-1-[(2S)-2-methylpyrrolidin-1-yl]ethyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide

ID: ALA5286810

Max Phase: Preclinical

Molecular Formula: C17H19F3N4O2

Molecular Weight: 368.36

Names and Identifiers

Canonical SMILES:  C[C@H]1CCCN1[C@@H](C)NC(=O)c1ccc(-c2noc(C(F)(F)F)n2)cc1

Standard InChI:  InChI=1S/C17H19F3N4O2/c1-10-4-3-9-24(10)11(2)21-15(25)13-7-5-12(6-8-13)14-22-16(26-23-14)17(18,19)20/h5-8,10-11H,3-4,9H2,1-2H3,(H,21,25)/t10-,11-/m0/s1

Standard InChI Key:  YJAMXBPNZSQSOR-QWRGUYRKSA-N

Molfile:  

 
     RDKit          2D

 26 28  0  0  0  0  0  0  0  0999 V2000
   -1.5444    1.3362    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8298    1.7485    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1180    1.3365    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1180    0.5114    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8281    0.0995    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5444    0.5077    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5966    1.7492    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5966    2.5743    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.3112    1.3365    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.0258    1.7492    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7405    1.3365    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.0258    2.5743    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4551    1.7491    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0739    1.1778    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7431    0.4433    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9190    0.5356    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3355   -0.0478    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2591    0.0951    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2591   -0.7300    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0632   -0.9802    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5340   -0.3265    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0420    0.3409    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2768   -1.7772    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6933   -2.3608    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0739   -1.9908    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4904   -2.5743    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  1  0
  4  3  2  0
  5  4  1  0
  1  6  1  0
  6  5  2  0
  3  7  1  0
  7  8  2  0
  7  9  1  0
  9 10  1  0
 10 11  1  0
 10 12  1  6
 13 11  1  0
 13 14  1  0
 14 15  1  0
 16 15  1  0
 11 16  1  0
 16 17  1  6
  6 18  1  0
 19 18  1  0
 19 20  2  0
 20 21  1  0
 22 21  1  0
 18 22  2  0
 20 23  1  0
 23 24  1  0
 23 25  1  0
 23 26  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5286810

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 368.36

Molecular Weight (Monoisotopic): 368.1460

AlogP: 3.32

#Rotatable Bonds: 4

Polar Surface Area: 71.26

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 7.20

CX LogP: 3.57

CX LogD: 3.35

Aromatic Rings: 2

Heavy Atoms: 26

QED Weighted: 0.90

Np Likeness Score: -1.51

References

1. Ahamad S, Bhat SA..  (2022)  The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington's Disease.,  65  (24.0): [PMID:36490325] [10.1021/acs.jmedchem.2c00799]

Source

Source(1):

• Scientific Literature